Company Overview and News

0
Stock With Momentum: CCM Duopharma Biotech

2018-06-22 theedgemarkets
CCM Duopharma Biotech Bhd (+ve) SHARES in CCM Duopharma Biotech Bhd (fundamental: 1.3/3, valuation: 1.4/3) triggered our proprietary momentum algorithm for the fifth time this year. Currently trading at about 1.89 times its book value, some 1.88 million shares were traded yesterday, exceeding the counter's 200-day average volume of 315,647 shares.
7148

5
CCM disposes of trademarks to CCM Duopharma

2018-04-11 thestar.com.my
KUALA LUMPUR: Chemical Company of Malaysia Bhd (CCM) has entered into sale and purchase agreement of trademarks and trademarks licence agreement with CCM Duopharma Biotech Bhd (CCMD).
7148 BSMAF 1818

20
PNB funds reach RM279b, 98pc invested locally

2018-03-18 themalaymailonline
Tan Sri Abdul Wahid Omar said PNB is today Malaysia’s largest fund manager. — Picture by Zuraneeza ZulkifliKUALA LUMPUR, March 18 — Permodalan Nasional Bhd (PNB), established some 40 years ago, is today the country’s largest fund manager, managing funds worth RM279 billion, said its Group Chairman, Tan Sri Abdul Wahid Omar.
MLYBY MLYNF 4197 7148 1155 4588 4863 5347 5258 SMEBF TNABY 6459 6888 AXXTF MYTEF TNABF BSMAF 1818

Related Articles

HIMX: Himax Technologies Analysis and Research Report

13h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...